RT Journal Article
SR Electronic
T1 Influenza outbreak, disease transmission rate and mortality risk in the United States (2021 to 2050 Projection)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.16.21255632
DO 10.1101/2021.04.16.21255632
A1 Etaware, Peter M.
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.16.21255632.abstract
AB Influenza and COVID-19 pandemics are among the deadliest respiratory diseases recorded in the history of humanity. Influenza infections are difficult to diagnose and nearly impossible to predict because the disease symptoms changes as the pathogen(s) evolve. The U.S. was the case study for this research (Latitude: 37.0902°N and Longitude: 95.7129°W). The principle employed in the design of the influenza forecast model was “The Integrated Independent System of Disease Prediction (IISDP)”, where the functionality of one forecast model depends on the predictive capacity of one or more forecast models. It was predicted that 49,734,427 individuals will be infected in 2021 out of the current estimation of 322,900.000 U.S. citizens (only about 1.5% of the total population). The situation was estimated by Etaware-Pred-2021 to worsen in 2050 (300,803,433 infected individuals out of the estimated 400,000,000 U.S. citizens), with a geometric increase in the ratio of infected individuals from 1.5% (in 2021) to 75.2% (in 2050), if necessary health precautions fail. unless there are potent influenza vaccines in circulation, total compliance to influenza vaccination and a high level of personal hygiene among U.S. citizens, influenza infection will become a global threat to humanity. These situations can be averted if the U.S. citizens act accordingly.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe data used for this research are secondary data and as such no registration or permission is requiredFunding StatementNo funding was received for this researchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None requiredAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesthe data used for this research are available for review. The data were submitted alongside the manuscript